 | | | | Related Healthscout Videos | |
|
(Ivanhoe Newswire) -- One-third of kidney failure patients have certain kinds of antigens in their body that put them at high risk for organ rejection. For these patients, the chances of receiving a new kidney are slim -- but thanks to newly developed techniques, they may now have the chance to receive a life-saving transplant.
Kidney transplant specialists at Cedars-Sinai Medical Center have opened the door to previously unsuitable patients in need of transplants by developing a new technology called a solid phase assay. Patients whose bodies have been highly exposed to substances called non-self human leukocyte antigens (HLAs) are likely to reject a new organ such as a kidney. HLAs can be picked up from blood transfusions, previous transplants or pregnancy. A solid phase assay uses beads coated with certain types of these substances to determine how resistant a patients body will be to a new organ.
Text Continues Below
This allows us to do a more quantitative analysis and predict more accurately which patients are the best candidates to have a successful transplant with a low risk of acute rejection, Nancy L. Reinsmoen, Ph.D., director of Cedars-Sinai Medical Centers HLA Laboratory and first author of the article, was quoted as saying.
If physicians find a patients body will resist a new kidney, they can then turn to a procedure called intravenous immunoglobulin (IVIG) to desensitize the body to the antigens that arrive with a new organ.
SOURCE: Transplantation, Sept. 27, 2008
Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.
This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.
|
